Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2008-07-08
2008-07-08
Chernyshev, Olga N (Department: 1649)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S004000, C435S007100, C435S007900, C435S007940, C436S501000, C436S503000, C436S063000
Reexamination Certificate
active
07396654
ABSTRACT:
The present invention identifies biomarkers that are diagnostic of nerve cell injury and/or neuronal disorders. Detection of different biomarkers of the invention are also diagnostic of the degree of severity of nerve injury, the cell(s) involved in the injury, and the subcellular localization of the injury.
REFERENCES:
patent: 5118606 (1992-06-01), Lynch et al.
patent: 5231000 (1993-07-01), Majocha et al.
patent: 5492812 (1996-02-01), Vooheis
patent: 6048703 (2000-04-01), Siman et al.
patent: 6589746 (2003-07-01), Zelman
patent: 2003/0040660 (2003-02-01), Jackowski et al.
patent: 2005/0260697 (2005-11-01), Wang et al.
patent: 2006/0246489 (2006-11-01), Svetlov et al.
patent: 2007/0003982 (2007-01-01), Hayes et al.
patent: WO 95/26506 (1995-10-01), None
Borghi, R. et al. “Full length alpha-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects”, 2000, Neuroscience Letters, 287:65-67.
Dambinova, S. et al. “The presence of autoantibodies to N-terminus domain of GluR1 subunit of AMPA receptor in the blood serum of patients with epilepsy”, 1997, Journal of Neurological Sciences, 152:93-97.
Dambinova, S. et al. “Blood Test Detecting Autoantibodies to N-Methyl-D-aspartate Neuroreceptors for Evaluation of Patients with Transient Ischemic Attack and Stroke”, 2003, Clinical Chemistry, 49(10):1752-1762.
Jakowec, M. et al. “The native form of alpha-synuclein is not found in the cerebrospinal fluid of patients with Parkinson's disease or normal controls”, 1998, Neuroscience Letters, 253:13-16.
Posmantur, R. et al. “A calpain inhibitor attenuates cortical cytoskeletal protein loss after experimental traumatic brain injury in the rat”, 1997, Neuroscience, 77(3):875-888.
Pike, B. et al. “Accumulation of non-erythroid alpha II-spectrin and calpain-cleaved alpha II-spectrin breakdown products in cerebrospinal fluid after traumatic brain injury in rats”, 2001, Journal of Neurochemistry, 78:1297-1306.
Rosengren, L. et al. “Patients with Amyotrophic Lateral Sclerosis and Other Neurodegenerative Diseases Have Increased Levels of Neurofilament Protein in CSF”, 1996, Journal of Neurochemistry, 67(5):2013-2018.
Zemlan, F. et al. “Quantification of Axonal Damage in Traumatic Brain Injury: Affinity Purification and Characterization of Cerebrospinal Fluid Tau Proteins”, 1999, Jounal of Neurochemistry, 72(2):741-750.
Sjogren, M. et al. “Neurofilament Protein in Cerebrospinal Fluid: A Marker of White Matter Changes”, 2001, Journal of Neuroscience Research, 66:510-516.
Shea, T. et al. “Calcium Influx into Human Neuroblastoma Cells Induces ALZ-50 Immunoreactivity: Involvement of Calpain-Mediated Hydrolysis of Protein Kinase C”, 1996, Journal of Neurochemistry, 66(4):1539-1549.
Denning, M. et al. “Protein Kinase C delta Is Activated by Capase-dependent Proteolysis during Ultraviolet Radiation-induced Apoptosis of Human Keratinocytes”, 1998, The Journal of Biological Chemistry, 273(45):29995-30002.
Koriyama, H. et al. “Proteolytic Activation of Protein Kinase C delta and epsilon by Capase-3 in U937 Cells During Chemotherapeutic Agent-Induced Apoptosis”, 1999, Cell Signal, 11(11):831-838.
Schwab, BL et al. “Cleavage of plasma membrane calcium pumps by caspases: a link between apoptosis and necrosis”, 2002, Cell Death and Differentiation, 9:818-831.
Hajimohammadreza, I. et al. “A Specific Inhibitor of Calcium/Calmodulin-Dependent Protein Kinase-II Provides Neuroprotection Against NMDA- and Hypoxia/Hypoglycemia-Induced Cell Death”, 1995, The Journal of Neuroscience, 15(5):4093-4101.
Hajimohammadreza, I.et al. “Neuronal Nitric Oxide Synthase and Calmodulin-Dependent Protein Kinase II alpha Undergo Neurotoxin-Induced Proteolysis”, 1997, Journal of Neurochemistry, 69(3):1006-1013.
Toyota, H. et al. “Calpain-induced Bax-clevage product is a more potent inducer of cell death than wild-type Bax”, 2003, Cancer Letters, 189:221-230.
McGinnist, K. et al. “Calcium/Calmodulin-dependent Protein Kinase IV Is Cleaved by Caspase-3 and Calpain in SH-SY5Y Human Neuroblastoma Cells Undergoing Apoptosis”, 1998, The Journal of Biological Chemistry, 273(32):19993-20000.
Cao, X. et al. “Cleavage of Bax to p18 Bax accelerates stress-induced apoptosis, and a cathespin-like protease may rapidly degrade p18 Bax”, 2003, Blood, 102(7):2605-2614.
Shigeta K. et al. “Fragmentation of a 70000-dalton calpastatin molecule upon its complex formation with calpain”, 1984, Biochem. Int., 9(3):327-33.
Mukerjee, N. et al. “Caspase-Mediated Calcineurin Activation Contributes to IL-2 Release during T Cell Activation”, 2001, Biochemical and Biophysical Research Communications, 285(5):1192-1199.
Estrov, et al, “Caspase 2 and Caspase 3 Protein Levels as Predictors of Survival in Acute Myelogenous Leukemia”,Blood, Nov. 1, 1998, pp. 3090-3097, vol. 92, No. 9.
Zaffaroni, M. “Biological Indicators of the Neurodegenerative Phase of Multiple Sclerosis”,Neurol Sci, 2003, pp. S279-S282, vol. 24.
Teunissen, C. E. et al. “Biochemical Markers Related to Alzheimer's Dementia in Serum and Cerebrospinal Fluid”,Neurobiology of Aging, 2002, pp. 485-508, vol. 23.
Tooney, P. A. et al. “Neurons Expressing Calcium-binding Proteins in the Prefrontal Cortex in Schizophrenia”,Progress in Neuro-Psychopharmacology&Biological Psychiatry, 2004, pp. 273-278, vol. 28.
Dekosky, S. T. et al. “Looking Backward to Move Forward: Early Detection of Neurodegenerative Disorders”,Science, Oct. 31, 2003, pp. 830-834, vol. 302.
Cutler, N. R. et al. “Review of the Next Generation of Alzheimer's Disease Therapeutics: Challlenges for Drug Development”,Prog. Neuro-Psychopharmacol.&Biol. Psychiat., 2001, pp. 27-57, vol. 25.
Blennow, K. “Cerebrospinal Fluid Protein Biomarkers for Alzheimer's Disease”,NeuroRx: The Journal of the American Society for Experimental NeuroTherapeutics, Apr. 2004, pp. 213-225, vol. 1.
Smith, D. H. et al. “Protein Accumulation in Traumatic Brain Injury”,NeuroMolecular Medicine, 2003, pp. 59-72, vol. 4.
Andreé, V. M. et al. “NMDA Receptor Alterations in Neurons from Pediatric Cortical Dysplasia Tissue”,Cerebral Cortex, Jun. 2004, pp. 634-646, vol. 14.
Ohta, M. et al. “Clinical and Analytical Evaluation of an Enzyme Immunoassay for Myelin Basic Protein in Cerebrospinal Fluid”,Clinical Chemistry, 2000, pp. 1326-1330, vol. 46, No. 9.
Taheri, S. et al. “The Role of Hypocretins (Orexins) in Sleep Regulation and Narcolepsy”,Annu. Rev. Neurosci., 2002, pp. 283-313, vol. 25.
Zhang, X. et al. “Phenotypes of T Cells Infiltrating the Eyes in Autoimmune Anterior Uveitis Associated with EAE”,Investigative Ophthalmology&Visual Science, May 2002, pp. 1499-1508, vol. 43, No. 5.
Everbroeck, B. V. et al. “A Prospective Study of CSF Markers in 250 Patients with Possible Creutzfeldt-Jakob Disease”,J. Neurol Neurosurg Psychiatry, 2003, pp. 1210-1214, vol. 74.
Inden, M. et al. “Proteasome Inhibitors Protect Against Degeneration of Nigral Dopaminergic Neurons in Hemiparkinsonian Rats”,J Pharmacol Sci, 2005, pp. 203-211, vol. 97.
Yohrling, G. J. et al. “Inhibition of Tryptophan Hydroxylase Activity and Decreased 5-HT1AReceptor Binding in a Mouse Model of Huntingdon's Disease”,Journal of Neurochemistry, 2002, pp. 1416-1423, vol. 82.
Pearl, P. L. et al. “Clinical Aspects of the Disorders of GABA Metabolism in Children”,Curr Opin Neurol, 2004, pp. 107-113, vol. 17.
Sanchez, J.-C. et al. “Cystatin C as a Potential Cerebrospinal Fluid Marker for the Diagnosis of Creutzfeldt-Jakob Disease”,Proteomics, 2004, pp. 2229-2233, vol. 4.
Wilson, K. E. et al. “Functional Genomics and Proteomics: Application in Neurosciences”,J Neurol Neuro
Hayes Ronald
Liu Ming Chen
Oli Monika
Wang Kevin Ka-Wang
Banyan Biomarkers, Inc.
Chernyshev Olga N
Saliwanchik Lloyd & Saliwanchik
University of Florida Research Foundation Inc.
LandOfFree
Neural proteins as biomarkers for traumatic brain injury does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Neural proteins as biomarkers for traumatic brain injury, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Neural proteins as biomarkers for traumatic brain injury will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2776928